These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12620421)

  • 1. Anti-HIV agents: design and discovery of new potent RT inhibitors.
    Barreca ML; Chimirri A; De Clercq E; De Luca L; Monforte AM; Monforte P; Rao A; Zappalà M
    Farmaco; 2003 Mar; 58(3):259-63. PubMed ID: 12620421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents.
    Barreca ML; Balzarini J; Chimirri A; De Clercq E; De Luca L; Höltje HD; Höltje M; Monforte AM; Monforte P; Pannecouque C; Rao A; Zappalà M
    J Med Chem; 2002 Nov; 45(24):5410-3. PubMed ID: 12431069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
    Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
    J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
    Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
    Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents.
    Barreca ML; Chimirri A; De Luca L; Monforte AM; Monforte P; Rao A; Zappalà M; Balzarini J; De Clercq E; Pannecouque C; Witvrouw M
    Bioorg Med Chem Lett; 2001 Jul; 11(13):1793-6. PubMed ID: 11425562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
    Tucker TJ; Saggar S; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    Bioorg Med Chem Lett; 2008 May; 18(9):2959-66. PubMed ID: 18396399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs.
    Yu M; Liu X; Li Z; Liu S; Pannecouque C; Clercq ED
    Bioorg Med Chem; 2009 Nov; 17(22):7749-54. PubMed ID: 19819705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
    Chimirri A; Grasso S; Monforte P; Rao A; Zappalà M; Monforte AM; Pannecouque C; Witvrouw M; Balzarini J; De Clercq E
    Antivir Chem Chemother; 1999 Jul; 10(4):211-7. PubMed ID: 10480739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
    J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Tian Y; Zhan P; Rai D; Zhang J; De Clercq E; Liu X
    Curr Med Chem; 2012; 19(13):2026-37. PubMed ID: 22429098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Murugesan V; Makwana N; Suryawanshi R; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Katti SB
    Bioorg Med Chem; 2014 Jun; 22(12):3159-70. PubMed ID: 24794742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Farmaco; 2004 Jan; 59(1):33-9. PubMed ID: 14751314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Chen W; Zhan P; Rai D; De Clercq E; Pannecouque C; Balzarini J; Zhou Z; Liu H; Liu X
    Bioorg Med Chem; 2014 Mar; 22(6):1863-72. PubMed ID: 24581546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Monforte AM; Ferro S; De Luca L; Lo Surdo G; Morreale F; Pannecouque C; Balzarini J; Chimirri A
    Bioorg Med Chem; 2014 Feb; 22(4):1459-67. PubMed ID: 24457088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of novel 2H-pyran-2-one derivatives as potential HIV-1 reverse transcriptase inhibitors.
    Defant A; Mancini I; Tomazzolli R; Balzarini J
    Arch Pharm (Weinheim); 2015 Jan; 348(1):23-33. PubMed ID: 25523431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
    Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
    J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.